Plasma Cell Myeloma: Clinical Trials

44 trials for Plasma Cell Myeloma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

22 completed, 10 active not recruiting, 6 terminated, 3 withdrawn. 44 Phase 2, 8 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 244Completed 22, Active not recruiting 10, Terminated 6, Withdrawn 3, Enrolling by invitation 1, Recruiting 1, Unknown 1
Phase 18Active not recruiting 3, Completed 3, Terminated 1, Withdrawn 1

Follow Plasma Cell Myeloma: new trials by email Literature Review of Plasma Cell Myeloma trials Research Report on Plasma Cell Myeloma

Trials (filtered) newest first · largest first

All 44 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
Belantamab Mafodotin, Lenalidomide - Plasma Cell Myeloma
Phase 2Active not recruitingRoswell Park Cancer Institute42024-08-192026-10-16
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone - Plasma Cell Myeloma
Phase 2Enrolling by invitationSanofi702023-04-052026-10-15
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma
Phase 1 / Phase 2Active not recruitingMayo Clinic492022-08-112026-10-16
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Belantamab Mafodotin, Dexamethasone, Pomalidomide - Plasma Cell Myeloma
Phase 2RecruitingEmory University342022-07-212026-09-03
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
Pembrolizumab - Plasma Cell Myeloma
Phase 2WithdrawnEmory University2022-04-112024-07-03
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1 - COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm
Phase 2Active not recruitingGeoVax, Inc.632021-09-272026-02-11
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
Selinexor, Dexamethasone Oral, Daratumumab - Multiple Myeloma, Myeloma Multiple
Phase 2Active not recruitingUS Oncology Research732021-09-102025-01-16
Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
Xisomab 3G3 - Lymphoma, Malignant Solid Neoplasm
Phase 2TerminatedOHSU Knight Cancer Institute92021-02-252024-01-24
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma, Renal Failure
Phase 2TerminatedEmory University172020-05-072024-07-01
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
Melphalan, Peripheral Blood Stem Cell Transplantation--CD34 HSCT, Peripheral Blood Stem Cell Transplantation--AHSCT - Plasma Cell Myeloma
Phase 2TerminatedUniversity of Nebraska82020-01-092024-03-12
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Laboratory Biomarker Analysis - Plasma Cell Myeloma, Secondary Amyloidosis
Phase 2Active not recruitingCity of Hope Medical Center312020-01-062026-10-20
Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation
Autologous Hematopoietic Stem Cell Transplantation, Filgrastim-sndz, Melphalan Hydrochloride - Plasma Cell Myeloma
Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center622019-10-092025-05-01
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
Anti-Thymocyte Globulin, Cyclophosphamide, Cytokine-treated Veto Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center162019-08-082026-06-11
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma
Phase 2UnknownEmory University492019-07-032024-06-21
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
Carfilzomib, Dexamethasone, Pomalidomide - Plasma Cell Myeloma
Phase 2Active not recruitingEmory University292019-01-252025-04-30
Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients
Carfilzomib, Daratumumab, Lenalidomide - Myeloma Multiple, Myeloma, Plasma-Cell
Phase 2CompletedTel-Aviv Sourasky Medical Center412018-05-022022-01-27
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Lenalidomide - Plasma Cell Myeloma
Phase 2CompletedMayo Clinic492018-04-092026-05-05
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
Busulfan, Cyclophosphamide, Fludarabine - Anemia, ASXL1 Gene Mutation
Phase 2TerminatedUniversity of Utah62018-03-302022-05-05
Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Isatuximab SAR650984, Cemiplimab REGN2810 - Plasma Cell Myeloma
Phase 1 / Phase 2CompletedSanofi1092018-02-212024-06-14
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim - Plasma Cell Leukemia in Remission, Plasma Cell Myeloma
Phase 1 / Phase 2WithdrawnCity of Hope Medical Center2018-01-012017-12-13

Showing 20 of 44. Sign in to see all of them.

Narrower conditions

Multiple Myeloma (44)  ·  Lymphoma, Non-Hodgkin (8)  ·  Leukemia, Myeloid, Acute (7)  ·  Hodgkin Disease (6)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (6)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6)  ·  Myelodysplastic Syndromes (6)  ·  Anemia, Aplastic (5)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (5)  ·  Myeloproliferative Disorders (4)  ·  Primary Myelofibrosis (4)  ·  Waldenstrom Macroglobulinemia (4)  ·  Leukemia, Myeloid, Chronic-Phase (3)  ·  Leukemia, Myelomonocytic, Chronic (3)  ·  Lymphoma (3)

Broader conditions

Blood Protein Disorders (44)  ·  Cardiovascular Diseases (44)  ·  Hematologic Diseases (44)  ·  Hemic and Lymphatic Diseases (44)  ·  Hemorrhagic Disorders (44)  ·  Hemostatic Disorders (44)  ·  Immune System Diseases (44)  ·  Immunoproliferative Disorders (44)  ·  Lymphoproliferative Disorders (44)  ·  Neoplasms by Histologic Type (44)  ·  Paraproteinemias (44)  ·  Vascular Diseases (44)  ·  Neoplasms (42)  ·  Neoplasms, Plasma Cell (42)  ·  Lymphatic Diseases (12)

Interventions

Lenalidomide (17)  ·  Dexamethasone (16)  ·  Cyclophosphamide (11)  ·  Calcium Dobesilate (10)  ·  Melphalan (9)  ·  daratumumab (9)  ·  Peripheral Blood Stem Cell Transplantation (7)  ·  Whole-Body Irradiation (7)  ·  auricularum (7)  ·  dexamethasone 21-phosphate (7)  ·  dexamethasone acetate (7)  ·  ixazomib (7)  ·  Mycophenolic Acid (6)  ·  Stem Cell Transplantation (6)  ·  Bortezomib (5)

Sponsors

M.D. Anderson Cancer Center (6)  ·  Mayo Clinic (6)  ·  Emory University (5)  ·  Fred Hutchinson Cancer Center (4)  ·  Roswell Park Cancer Institute (3)  ·  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (3)  ·  City of Hope Medical Center (2)  ·  SWOG Cancer Research Network (2)  ·  Sanofi (2)  ·  GeoVax, Inc. (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  National Cancer Institute (NCI) (1)  ·  OHSU Knight Cancer Institute (1)  ·  Ohio State University Comprehensive Cancer Center (1)  ·  Tel-Aviv Sourasky Medical Center (1)

Countries

United States (43)  ·  Italy (3)  ·  Australia (2)  ·  Brazil (2)  ·  Czechia (2)  ·  France (2)  ·  Greece (2)  ·  Spain (2)  ·  Canada (1)  ·  Chile (1)  ·  China (1)  ·  Denmark (1)  ·  Finland (1)  ·  Hungary (1)  ·  Israel (1)

Top investigators

Ajay Nooka, MD, MPH (2)  ·  Brenda Sandmaier (2)  ·  Shaji Kumar (2)  ·  Shaji Kumar, M.D. (2)  ·  Ajay K Nooka, MD,MPH,FACP (1)  ·  Ajay K. Nooka, MD,MPH,FACP (1)  ·  Alexander Lesokhin, MD (1)  ·  Amrita Y Krishnan (1)  ·  Andrzej Jakubowiak (1)  ·  Ann E. Dahlberg (1)  ·  Catherine Lee, MD (1)  ·  Choon-Kee Lee, MD (1)  ·  Christopher D'Angelo, MD (1)

Results publications

PMID 29246938, PMID 32603426, PMID 33619369, PMID 34048681, PMID 34182226, PMID 35285981, PMID 35737873, PMID 37970718, PMID 42537695

NIH funding

P30CA138292 (5), P30CA015704 (2), U10CA032102 (2), 2017 (1), 2023 (1), P01CA018029 (1), P01CA078902 (1), P30CA014599 (1), P30CA015083 (1), P30CA033572 (1), R01HL151367 (1)